Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Argenteuil – page 193

3 430 clinical trials in Argenteuil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Argenteuil at a glance
3 430
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 430 trials in Argenteuil

Open in trial search

Nephrotic syndrome

Not recruiting

Study of Rituximab, Prednisolone and Betamethasone in Adult Patients with First Episode of Minimal Change Nephrotic Syndrome to Prevent Disease Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RLY-4008
  • Sponsor:Elevar Therapeutics Inc.

Acute myeloid leukaemia+1

Not recruiting

Study of Emavusertib for Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emavusertib
  • Sponsor:Curis Inc.

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brigimadlin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Preventing Post-Operative Atrial Fibrillation with Botulinum Toxin Injections in Patients Undergoing Cardiac Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:IncobotulinumtoxinA
  • Sponsor:Assistance Publique Hopitaux De Paris

Endometrial cancer+1

Not recruiting

Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Netris Pharma

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Argenteuil

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel treatment combinations and maintenance therapies. Studies include investigations of follicular lymphoma and chronic lymphocytic leukemia treatments.

  • Multiple Myeloma Therapy Optimization
  • Lymphoma Treatment Advances
  • Novel Drug Combinations

Particular emphasis on improving patient outcomes through targeted therapies and immunological approaches.

02 Immunology and Infectious Diseases

Clinical trials examining treatments for invasive candidiasis and immune system disorders. Research includes studies on immunosuppression prevention and management in intensive care settings.

  • Antifungal Treatments
  • Immune System Modulation
  • Critical Care Interventions

Focus on developing more effective treatments for both acute and chronic immune conditions.

03 Respiratory and Inflammatory Conditions

Studies investigating treatments for asthma and severe respiratory infections, including community-acquired pneumonia. Research includes evaluation of new delivery systems and therapeutic approaches.

  • Asthma Management
  • Pneumonia Treatment
  • Respiratory Drug Delivery

Emphasis on improving treatment outcomes and patient quality of life through innovative therapeutic strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.